Post
ESCMID 2024: Emerging bacterial infections in neonates and children
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, emerging …
Biotechs must prioritise ethics to deter GenAI “bad actors”
AI developers in the biotechnology field need to watch out for potential “bad actors”, who could use the technology for …
Zenas raises $200m to advance autoimmune antibody therapy
US-based Zenas BioPharma has raised $200m in a Series C round to support the clinical development of its lead candidate, …
FDA fast track status granted to iECURE neonatal OTC deficiency treatment
The US Food and Drug Administration (FDA) has granted fast track designation for iECURE’s gene editing therapy, ECUR-506, for the …
AstraZeneca to withdraw Covid-19 vaccine globally
AstraZeneca has begun the global withdrawal of its Covid-19 vaccine, Vaxzevria, citing a surplus of updated vaccines designed to combat …
How six trends are driving pharmaceutical milling
Manufacturing capacity, safety and increasing costs are among the main concerns for drug manufacturers and CMOs. These crucial elements are …
BioVersys and GSK expand their partnership for TB treatment alpibectir
BioVersys and GSK have announced the expansion of their strategic partnership to expedite the clinical development of alpibectir (BVL-GSK098) to …
TerSera’s ZOLADEX LA gains Health Canada approval for breast cancer
TerSera has obtained Health Canada's approval for a supplemental new drug submission for ZOLADEX LA (goserelin acetate) 10.8mg administered every …
Broken String Biosciences teams up with Francis Crick Institute for ALS research
Broken String Biosciences has teamed up with the Francis Crick Institute to conduct research into the role of genome stability …
Psilocybin effective in treating depression
A new study published in the British Medical Journal found potential in the use of psilocybin to treat depression, with …
Vertex reports net profits of $2.69bn in Q1 2024
Vertex has reported that its net revenues grew to $2.69bn in Q1 2024, displaying a 13% increase from earnings reported …
BioNTech reports net loss of €315.1m in Q1 2024
BioNTech has experienced a significant shift in its financial standing, reporting a net loss of €315.1m ($339.3m) in the first …
China’s NMPA grants breakthrough therapy status for Innovent’s IBI343
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) for …
Gossamer Bio and Chiesi partner for pulmonary hypertension treatment
Gossamer Bio and Chiesi Farmaceutici (the Chiesi Group) have announced a worldwide partnership and licence agreement to develop and market …
AstraZeneca concludes equity investment in Cellectis
AstraZeneca has concluded an equity investment in clinical-stage biotechnology company Cellectis. The investment comes after the companies entered an equity investment …